title: Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab.
abstract: The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can succeed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment.
authors.affiliation: College of Medicine, Mayo Clinic.
authors.forename: George P
authors.initials: GP
authors.lastname: Kim
authors.forename: Axel
authors.initials: A
authors.lastname: Grothey
references.citation: J Clin Oncol. 2002 Sep 15;20(18 Suppl):1S-13S
references.pmid: 12235219
references.citation: Clin Colorectal Cancer. 2007 Mar;6(6):427-32
references.pmid: 17531105
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1626-34
references.pmid: 18316791
references.citation: N Engl J Med. 2004 Dec 30;351(27):2883
references.pmid: 15625347
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):165-74
references.pmid: 10882302
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1201-8
references.pmid: 14993230
references.citation: Cancer. 2007 Sep 1;110(5):980-8
references.pmid: 17671985
references.citation: J Clin Oncol. 2001 Sep 15;19(18 Suppl):41S-44S
references.pmid: 11560970
references.citation: J Clin Oncol. 2008 May 10;26(14):2311-9
references.pmid: 18390971
references.citation: Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90
references.pmid: 14967460
references.citation: N Engl J Med. 2007 Nov 15;357(20):2040-8
references.pmid: 18003960
references.citation: Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
references.pmid: 16829981
references.citation: Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23
references.pmid: 11255078
references.citation: Cell. 1990 Jun 1;61(5):759-67
references.pmid: 2188735
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4557-61
references.pmid: 17876013
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4914-21
references.pmid: 17050875
references.citation: J Clin Oncol. 2007 May 1;25(13):1658-64
references.pmid: 17470858
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1803-10
references.pmid: 15677699
references.citation: Cancer Res. 1989 Sep 1;49(17):4682-9
references.pmid: 2547513
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3644-8
references.pmid: 17704414